GlassScriptPhysician profile
Sylvia Jaramillo
NPI 1407089642
$3,447.36
in general payments reported to CMS, 2019-2025
37 companies · $870 in 2025
The $870 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $270 · 2020: $12.06 · 2021: $123 · 2022: $281 · 2023: $681 · 2024: $1,210 · 2025: $870.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,689 · Education: $72.01.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,689.15 |
| Education | $72.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $806.55 | 2019-2025 | Tecvayli, Darzalex, Erleada |
| Merck Sharp & Dohme LLC | $253.71 | 2019-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Astrazeneca Pharmaceuticals LP | $208.61 | 2022-2025 | Imfinzi, Calquence, Enhertu |
| Beigene USA, INC. | $169.91 | 2023 | Brukinsa |
| E.R. Squibb & Sons, L.L.C. | $163.29 | 2020-2025 | Opdivo |
| Celgene Corporation | $159.87 | 2022-2025 | Reblozyl, Opdivo |
| Incyte Corporation | $157.61 | 2021-2024 | Jakafi, Monjuvi |
| Pfizer INC. | $151.93 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $141.06 | 2019-2025 | |
| Gilead Sciences, INC. | $121.01 | 2021-2025 | Trodelvy |
| Covidien LP | $96.42 | 2019 | |
| Tempus Ai, INC | $91.84 | 2024 | |
| Eisai INC. | $75.36 | 2023-2024 | |
| Daiichi Sankyo INC. | $74.90 | 2023-2025 | Enhertu |
| Abbvie INC. | $71.71 | 2025 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $65.26 | 2024-2025 | Vyloy |
| Regeneron Healthcare Solutions, INC. | $58.73 | 2024-2025 | Libtayo |
| Array Biopharma INC | $58.30 | 2024-2025 | Mektovi, Braftovi, Lorbrena |
| Seagen INC. | $55.10 | 2022-2023 | Padcev |
| Shield Therapeutics INC | $48.89 | 2024 | |
| Genzyme Corporation | $40.15 | 2024 | |
| Stemline Therapeutics INC. | $38.48 | 2023-2024 | Orserdu |
| Lilly USA, LLC | $37.89 | 2022-2023 | Verzenio |
| Puma Biotechnology, INC. | $37.16 | 2023-2024 | |
| Servier Pharmaceuticals LLC | $30.05 | 2025 | |
| Genmab U.S., INC. | $29.46 | 2024 | Epkinly |
| Aveo Pharmaceuticals, INC. | $27.29 | 2023 | Fotivda |
| Takeda Pharmaceuticals U.S.A., INC. | $24.03 | 2024 | Iclusig |
| Sobi, INC | $21.76 | 2025 | |
| Janssen Scientific Affairs, LLC | $21.67 | 2023 | Rybrevant |
| Blueprint Medicines Corporation | $19.15 | 2025 | Ayvakit |
| Emd Serono, INC. | $18.38 | 2024 | |
| Agios Pharmaceuticals, INC. | $16.17 | 2024 | |
| Kite Pharma, INC. | $15.08 | 2023 | |
| Jazz Pharmaceuticals INC. | $14.18 | 2025 | |
| Genentech USA, INC. | $13.39 | 2024 | Tecentriq, Tecentriq Hybreza, Polivy |
| Janssen Pharmaceuticals, INC | $13.01 | 2023 | Xarelto |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sylvia Jaramillo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.